Henan Cancer Hospital: Carcinoma trials
The registry lists 12 Carcinoma studies with Henan Cancer Hospital as lead sponsor. 7 are open to participants now and 0 have results posted.
Phase 2 6Phase 3 2No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract CarcinomaRecruitingNCT06749730Phase 2
- Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNCT06478927Not applicable
- Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of SkinRecruitingNCT05886140Not applicable
- Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05495152Phase 3
- Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell CarcinomaRecruitingNCT05490485Phase 2
- Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial CarcinomaRecruitingNCT05276167Not applicable
- Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)RecruitingNCT04138212Phase 3
- Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of RecurrenceStatus unknownNCT05545124Phase 2
- Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04229849Phase 2
- Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.Status unknownNCT04063683Phase 2
- A Real World Study of Apatinib in Treatment of Patients With Gastric CarcinomaStatus unknownNCT03735511
- A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT03424291Phase 2